Overview
Insulet Corporation (NASDAQ:PODD) disclosed a voluntary Medical Device Correction for particular lots of its Omnipod product line, prompting a roughly 6% decline in the company's shares during after-hours trading on Tuesday. The action covers defined lots of Omnipod 5, Omnipod DASH, and Omnipod Insulin Management System (Omnipod Eros) Pods sold in the U.S. and certain international markets.
Nature of the issue
The company determined that a manufacturing issue can produce a small tear in the tubing located just above the skin surface on some Pods. That tear may permit insulin to leak outside the Pod instead of being delivered into the user, resulting in under-delivery of insulin.
Scope and reported events
Approximately 7 million Pods fall within the scope of this correction, equal to about 8.5% of Insulet's projected 2025 global Omnipod Pod production. Insulet reports that about 60% of the affected Pods have already been consumed or are expired. Globally, the company has recorded 24 serious adverse events tied to elevated blood glucose levels, including hospitalization and diabetic ketoacidosis; no deaths have been reported in connection with these events.
Relationship to prior actions
This Medical Device Correction is separate from a prior voluntary correction announced on March 12, 2026, which addressed certain Omnipod 5 Pods in the U.S. The company notes the two actions are distinct.
Company response and remediation
Insulet said it identified the root cause of the manufacturing defect and has implemented corrective steps aimed at preventing recurrence. The company has reinforced in-process monitoring and quality-control measures to detect cannula tears during production.
Customers affected by the correction are being contacted directly. Insulet is providing guidance to help users identify impacted lot numbers, discontinue use of affected Pods, and obtain replacement Pods at no charge. The company stated it has sufficient inventory to replace impacted Pods and does not expect this correction to disrupt product availability.
Regulatory notification
Insulet notified the U.S. Food and Drug Administration and other relevant regulatory authorities of the Medical Device Correction.
Market reaction
Following the announcement, Insulet's stock moved lower in after-hours trading, reflecting investor reaction to the recall and associated operational and reputational considerations.
Summary of key facts
- Voluntary Medical Device Correction announced for specific Omnipod Pod lots.
- About 7 million Pods included - roughly 8.5% of 2025 global Pod production; ~60% already consumed or expired.
- Company reports 24 serious adverse events globally; no deaths reported.
- Insulet has identified the cause, strengthened controls, will provide free replacements, and notified regulators.